Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 5/8/2020
SIETES contiene 93082 citas

 1 a 20 de 124 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Haight BR, Learned SM, Lafont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Linq W, Heidbreder C, RB-US-13-0001 Study Investigators. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2019;393:23 de febrero. [Ref.ID 103111]
2.Tiene citas relacionadas Cita con resumen
Manhapra A, Rosenheck R. Opioid substitution treatment is linked to reduced risk of death in opioid use disorder. BMJ 2017;357:j1947. [Ref.ID 101635]
3.Tiene citas relacionadas Cita con resumen
Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017;357:j1550. [Ref.ID 101634]
4. Cita con resumen
Nielsen S, Larance B, Lintzeris N. Opioid agonist treatment for patients with dependence on prescriptions opioids. JAMA 2017;317:967-8. [Ref.ID 101470]
5.Tiene citas relacionadas Cita con resumen
Dunlap B, Cifu AS. Clinical management of opioid use disorder. JAMA 2016;316:338-9. [Ref.ID 100637]
6.Tiene citas relacionadas Cita con resumen
Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ, for the PRO-814 Study Group. Effect of buprenorphine implant on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial. JAMA 2016;316:282-90. [Ref.ID 100636]
7. Cita con resumen
Anónimo. FDA approves first buprenorphine implant for treatment of opioid dependence. U.S. Food and Drug Administration 2016:26 de mayo. [Ref.ID 100323]
8. Cita con resumen
Shaheed CA, Maher CG, Williams KA, Day R, McLachlan AJ. Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: a systematic review and meta-analysis. JAMA Intern Med 2016;176:958-68. [Ref.ID 100298]
9. Cita con resumen
McCarthy M. US needs $1.1bn to treat opioid addiction. BMJ 2016;352:i694. [Ref.ID 100047]
10. Cita con resumen
11. Cita con resumen
Anónimo. Dangers de l'anorexigène Mysimba: mobilisation citoyenne bienvenue. Prescrire 2015;35:305. [Ref.ID 99129]
Farrell M, Wodak A, Gowing L. Maintenance drugs to treat opioid dependence. BMJ 2012;344:45-9. [Ref.ID 93164]
14. Cita con resumen
Anónimo. Opioïdes et hypogonadisme. Prescrire 2012;32:27-8. [Ref.ID 92255]
15. Cita con resumen
Lacroix I, Berrebi A, Garipuy D, Schmitt L, Hammou Y, Chaumerliac C, Lapeyre-Mestre M, Montastruc J-L, Damase-Michel C. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol 2011;67:1053-9. [Ref.ID 91555]
16.Enlace a cita original
Zamparutti G, Schifano F, Corkery JM, Oyefeso A, Ghodse AH. Deaths of opiate/opioid misusers involving dihydrocodeine, UK, 1997-2007. Br J Clin Pharmacol 2011;72:330-7. [Ref.ID 91098]
17. Cita con resumen
Anónimo. Transdermal buprenorphine (Butrans) for chronic pain. Med Lett Drugs Ther 2011;53:31-2. [Ref.ID 90668]
Anónimo. Héroïne sur prescription et sous surveillance médicalisée. Prescrire 2011;31:210-1. [Ref.ID 90312]
19. Cita con resumen
Anónimo. Buprenorphine during pregnancy. JAMA 2011;305:348. [Ref.ID 90112]
20.Tiene citas relacionadas
O'Connor PG. Buprenorphine implants and opioid dependence. In reply. JAMA 2011;305:254-5. [Ref.ID 90092]
Seleccionar todas
 1 a 20 de 124 siguiente >>